PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1462774
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1462774
Cancer Vaccines Drug Pipeline Market Forecasts to 2030 - Global Analysis By Type, Cancer Type,Technology, End User and By Geography
According to Stratistics MRC, the Global Cancer Vaccines Drug Pipeline Market is accounted for $6.46 billion in 2023 and is expected to reach $23.17 billion by 2030 growing at a CAGR of 20.0% during the forecast period. The Cancer Vaccines Drug Pipeline is the ongoing research and development efforts focused on creating vaccines for preventing, treating, or managing cancer. These vaccines work by stimulating the body's immune system to recognize and attack cancer cells, offering a potentially targeted and less invasive approach to cancer treatment. The pipeline includes various stages of development, from early preclinical research to clinical trials, with the ultimate goal of bringing safe and effective cancer vaccines to market.
According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018.
Market Dynamics:
Driver:
Rising incidence of cancer
As more individuals face the threat of cancer, the demand for effective preventative and therapeutic solutions like vaccines surges. This urgency incentivizes research and development efforts, pushing scientists to explore, innovate, and refine vaccine technologies, ultimately expanding the pipeline with the hope of combating this growing global health challenge. Therefore, these factors are accelerating market growth.
Restraint:
Complex development process
Many cancer vaccines in the pipeline demonstrate limited efficacy in clinical trials, raising concerns about their effectiveness in preventing or treating cancer. Also, safety concerns regarding potential side effects and immune reactions can create hesitancy among patients and healthcare professionals. The complex process discourages some companies from entering the market, hindering the overall development and diversification of the pipeline.
Opportunity:
Combination therapies
Integrating cancer vaccines with other established therapies, such as chemotherapy, immunotherapy, or targeted therapies, presents a unique opportunity to revolutionize cancer treatment and improve patient outcomes. This approach holds promise for improving treatment outcomes, minimising adverse effects, and potentially extending patient survival. By leveraging the complementary mechanisms of action of various therapies, combination strategies aim to address the multifaceted nature of cancer, paving the way for more effective and personalised treatment approaches in the ongoing battle against this complex disease.
Threat:
Regulatory hurdles
Stringent regulatory requirements, including lengthy approval processes and complex clinical trial protocols, can delay market entry and increase development costs. Uncertainty surrounding evolving regulatory guidelines and stringent safety standards may deter investment in cancer vaccine research and development. Also, varying regulatory standards across different regions and jurisdictions further complicate the market landscape, potentially limiting global market access.
Covid-19 Impact
The COVID-19 pandemic has diverted resources, attention, and funding away from cancer research and development, slowing down progress in vaccine discovery and clinical trials. Lockdown measures disrupted supply chains and halted clinical trials, delaying the advancement of potential cancer vaccines. Despite these setbacks, the pandemic has also spurred innovation and collaboration in vaccine development, leading to the accelerated adoption of telemedicine and remote clinical trial monitoring, which may benefit the cancer vaccine pipeline market in the long term.
The prophylactic vaccine segment is expected to be the largest during the forecast period
The prophylactic vaccine segment is estimated to hold the largest share. The prophylactic vaccine focuses on preventing the development of cancer by targeting specific infectious agents known to cause certain types of cancer. These vaccines work by stimulating the immune system to recognise and destroy pathogens, such as viruses or bacteria that are linked to cancer development. Moreover, by preventing infection with these carcinogenic agents, prophylactic vaccines aim to reduce the risk of developing associated cancers.
The lung cancer segment is expected to have the highest CAGR during the forecast period
The lung cancer segment is anticipated to have lucrative growth during the forecast period. This segment focuses on the development of vaccines specifically designed to prevent or treat lung cancer. These vaccines target antigens present in lung cancer cells, aiming to trigger the body's immune response against tumour cells. With lung cancer being a significant global health concern, the development of effective vaccines holds promise for reducing its burden and improving patient survival rates.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period owing to the rising prevalence of cancer in the region, coupled with increasing awareness and adoption of preventive measures. China is the largest market, driven by its large population, growing biotechnology sector, and favourable regulatory policies. Regulatory frameworks in many Asian countries are becoming more streamlined and efficient, facilitating the development and approval of new cancer vaccines. Moreover, governments in the region are actively supporting cancer research and development, including funding for vaccine development and clinical trials.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period. North America faces a significant burden of cancer, with several types prevalent across the region. This drives demand for effective preventive and therapeutic options. Also, the region boasts leading research institutions, pharmaceutical companies, and biotechnology firms actively engaged in developing innovative cancer vaccines. Both government agencies and private investors significantly contribute to funding cancer research and development, including vaccine programs.
Key players in the market
Some of the key players in the Cancer Vaccines Drug Pipeline Market include AstraZeneca, F. Hoffmann-La Roche, Merck & Co., Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline (GSK), Moderna, Novartis, Bristol-Myers Squibb, BioNTech, Genentech, Bavarian Nordic, Takeda Pharmaceuticals, OncoGenex Pharmaceuticals, Northwest Biotherapeutics, Vaxil Bio, Immunomic Therapeutics, Transgene and Arbor Pharmaceuticals.
Key Developments:
In February 2024, AstraZeneca unveils successes in treatment of lung cancer, with its leading drug slowing progression of the disease at an early stage. AstraZeneca also announced that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free survival by almost nine months.
In December 2023, AstraZeneca ties up with AI Biologics Company to develop cancer drug. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy - a leading focus of Anglo-Swedish drugmaker AstraZeneca.
Types Covered:
- Prophylactic Vaccine
- Therapeutic Vaccine
Cancer Types Covered:
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Colorectal Cancer
- Other Cancer Types
Technologies Covered:
- Recombinant Vaccines
- Viral Vector Vaccines
- Whole-Cell Vaccines
- DNA Vaccines
- Other Technologies
End Users Covered:
- Hospital
- Ambulatory Care Centers
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Cancer Vaccines Drug Pipeline Market, By Type
- 5.1 Introduction
- 5.2 Prophylactic Vaccine
- 5.3 Therapeutic Vaccine
6 Global Cancer Vaccines Drug Pipeline Market, By Cancer Type
- 6.1 Introduction
- 6.2 Breast Cancer
- 6.3 Prostate Cancer
- 6.4 Lung Cancer
- 6.5 Colorectal Cancer
- 6.6 Other Cancer Types
7 Global Cancer Vaccines Drug Pipeline Market, By Technology
- 7.1 Introduction
- 7.2 Recombinant Vaccines
- 7.3 Viral Vector Vaccines
- 7.4 Whole-Cell Vaccines
- 7.5 DNA Vaccines
- 7.6 Other Technologies
8 Global Cancer Vaccines Drug Pipeline Market, By End User
- 8.1 Introduction
- 8.2 Hospital
- 8.3 Ambulatory Care Centers
9 Global Cancer Vaccines Drug Pipeline Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 AstraZeneca
- 11.2 F. Hoffmann-La Roche
- 11.3 Merck & Co.
- 11.4 Pfizer
- 11.5 Johnson & Johnson
- 11.6 Sanofi
- 11.7 GlaxoSmithKline (GSK)
- 11.8 Moderna
- 11.9 Novartis
- 11.10 Bristol-Myers Squibb
- 11.11 BioNTech
- 11.12 Genentech
- 11.13 Bavarian Nordic
- 11.14 Takeda Pharmaceuticals
- 11.15 OncoGenex Pharmaceuticals
- 11.16 Northwest Biotherapeutics
- 11.17 Vaxil Bio
- 11.18 Immunomic Therapeutics
- 11.19 Transgene
- 11.20 Arbor Pharmaceuticals
List of Tables
- Table 1 Global Cancer Vaccines Drug Pipeline Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 4 Global Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 5 Global Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 6 Global Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 7 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 8 Global Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 9 Global Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 10 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 11 Global Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 12 Global Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 13 Global Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 14 Global Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 15 Global Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 16 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 17 Global Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 18 Global Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 19 Global Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 20 North America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
- Table 21 North America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 22 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 23 North America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 24 North America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 25 North America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 26 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 27 North America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 28 North America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 29 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 30 North America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 31 North America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 32 North America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 33 North America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 34 North America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 35 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 36 North America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 37 North America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 38 North America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 39 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
- Table 40 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 41 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 42 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 43 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 44 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 45 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 46 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 47 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 48 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 49 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 50 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 51 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 52 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 53 Europe Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 54 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 55 Europe Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 56 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 57 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 58 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
- Table 59 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 60 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 61 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 62 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 63 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 64 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 65 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 66 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 67 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 68 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 69 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 70 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 71 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 72 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 73 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 74 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 75 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 76 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 77 South America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
- Table 78 South America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 79 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 80 South America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 81 South America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 82 South America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 83 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 84 South America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 85 South America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 86 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 87 South America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 88 South America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 89 South America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 90 South America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 91 South America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 92 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 93 South America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 94 South America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 95 South America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 96 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
- Table 97 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
- Table 98 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
- Table 99 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
- Table 100 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
- Table 101 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
- Table 102 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 103 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
- Table 104 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
- Table 105 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
- Table 106 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
- Table 107 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 108 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
- Table 109 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
- Table 110 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
- Table 111 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 112 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
- Table 113 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
- Table 114 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
